swiss medicaHematopoietic stem cell transplantation (HSCT) is a cutting-edge medical procedure that offers new hope to patients with chronic life-threatening conditions. This advanced approach replaces damaged native bone marrow tissue with healthy hematopoietic stem cells (HSCs), which have the ability to grow into new blood and immune cells.
The therapeutic potential of stem cells has advanced significantly, shifting from experimental stages to clinically proven therapy that gives promising results. However, the HSCT procedure also involves significant medical complexity and potential risks, making careful evaluation and monitoring essential parts of the treatment process.
What Is Hematopoietic Stem Cell Transplantation?
HSCT transplant is a medical procedure that focuses on restoring the body’s blood-forming system. The term “hematopoietic” refers to the process of forming new blood cells—hematopoiesis, which takes place in the bone marrow.
They are usually collected from the patient’s own bone marrow or blood, donor bone marrow or blood, or umbilical cord blood. Once collected, they are used in an HSCT stem cell treatment to help the body regenerate healthy tissue.
Why HSCT Can Be Life-Saving
The blood and immune systems are the body’s central defense and support networks.
In the absence of healthy blood cells, wounds do not heal, infections are not prevented, and oxygen is not delivered to tissues. In cancers such as leukemia, malignant cells take over the bone marrow, and in immune disorders such as multiple sclerosis, the body attacks itself.
HSCT therapy offers not just symptom relief, but a way to rebuild these systems from the ground up. By replacing malfunctioning bone marrow with healthy stem cells, patients can regain the ability to produce healthy cells—often leading to long-term remission or even a cure when no other treatments are effective.
Advantages of hematopoietic stem cell transplantation
- Rebuilding the immune system;
- Destroying cancerous or faulty cells;
- Offering hope when other treatments fail;
Interested in stem cell therapies? Discover the types of stem cells we use at Swiss Medica and how they support our regenerative treatments.
Read the articleConditions Treated with HSCT
HSCT treatment is used in a range of chronic conditions, many of which were once considered untreatable. Below are key areas where this therapy has transformed outcomes for patients and families.
Multiple Sclerosis
There is an important approach in managing multiple sclerosis (MS) that combines hematopoietic stem cell transplantation with chemotherapy.
Research studies support the validity of this method, showing promising outcomes in stopping disease progression and resetting the immune system. Patients frequently experience improvements in their everyday functioning, thinking, and movement. The approach gives hope, especially in the earlier, inflammatory stages of MS.
Get a free online consultation
If someone close to you is affected by multiple sclerosis, our team is here to help. Reach out to speak with an expert in regenerative medicine and learn more about the treatments available.
Medical Advisor, Swiss Medica doctor
Other Conditions
Beyond multiple sclerosis, HSCT has been the subject of scientific research for several other chronic medical conditions. For example, in the treatment of blood cancers like lymphoma, HSCT transplants can be effective. In some cases, particularly in aggressive or relapsing forms, it can improve the overall prognosis.
Inherited immune disorders represent another field where HSCT offers hope. By providing the patient with healthy progenitor cells, HSCT treatment has been shown to enhance the functioning of the immune system. This effect provides life quality improvement, mostly in individuals who might face life-threatening complications from common infections.
In rare metabolic diseases, such as certain enzyme deficiencies, transplantation of hematopoietic stem cells has been studied as a means to restore absent metabolic functions. Introducing healthy stem cells can help correct specific biochemical imbalances and potentially slow the inherited disease progression.
Types of HSCT: What’s the Difference?
There are two primary sources used in HSCT treatment: the patient’s own stem cells (autologous) and stem cells from a donor (allogeneic). Each type has distinct characteristics, influencing how the treatment functions and which patient populations it is best suited for.
Autologous Transplant
This type uses the patient’s own stem cells. This approach avoids immune complications because the patient’s own immune cells are used. It is mainly used when the patient’s condition allows the use of their own healthy cells.
Allogeneic Transplant
This method uses stem cells from another person, usually from a matched donor. The major benefit is that the patient’s condition can be fought off with the help of the donor’s HSC. However, this type of transplant carries a risk of immune-related complications.
Umbilical Cord Blood Transplant
This method uses stem cells derived from donated umbilical cord blood. Cord blood transplants can be particularly beneficial for children and patients with rare tissue types. However, recovery may take longer compared to other forms of HSCT.
Haploidentical Transplant
This option uses a donor who is only a half-match, often a parent, child, or sibling. It opens up possibilities for patients who cannot find a full match, making HSCT therapy available to more people.
HSC transplants are not the only option. Swiss Medica has extensive experience with mesenchymal stem cells (MSCs), offering patients a safe and effective approach to regenerative treatment.
Read this articleThe Transplant Process
The HSCT stem cell transplant journey consists of several carefully coordinated phases, each essential to the overall success of the treatment.
The process begins with a thorough medical examination and, if necessary, finding a suitable donor. This is followed by the transplant procedure, which may be preceded by conditioning therapy, depending on the patient’s condition.
After the HSCT stem cell transplant, patients are closely monitored to ensure the introduced hematopoietic stem cells establish and function correctly.
How Donors Are Matched and Selected
In allogeneic HSC transplants, donor stem cells—which carry high levels of HLA expression—are introduced into the recipient’s body.
Finding the right donor for HSCT stem cell transplant is critical for the success of the procedure. Specialists focus on matching human leukocyte antigens (HLA), which are key immune system markers present on the surface of cells. These markers play a central role in how the immune system recognizes the own patient cells.
A close HLA match between donor and recipient significantly lowers the risk of immune complications, such as graft-versus-host disease (GVHD), and improves transplant outcomes. This is why careful HLA typing and matching are essential steps in the donor selection process.
Potential Side Effects and Complications
Careful donor-recipient matching is essential to reduce the risk of immune rejection. To further minimize this risk, patients must also undergo immunosuppressive therapy.
However, even with these precautions, several significant complications may arise.
- Graft-versus-host disease (GVHD): An immune response in which the transplanted cells attack the tissues of the recipient.
- Infections: Because the immune system is weakened during and after the transplant, patients are highly vulnerable to infections.
- Hepatic and urinary issues: Strong immunosuppressive therapy or radiation used before the transplant can sometimes damage the organs.
- Risk of disease relapse: In some cases, disease can return even after a successful transplant.
That’s why choosing an experienced, trusted HSCT treatment center is key to ensuring the best possible outcome.
Get a free online consultation
At Swiss Medica, we always strive to maximize the effectiveness of our therapy and therefore offer safer treatment options. Contact us to find out more.
Medical Advisor, Swiss Medica doctor
Factors That Influence HSCT Outcomes
| Age | Young patients often show better recovery, while older patients may face more complications. |
| General health | Patients in good overall health before the transplant tend to have higher success rates and fewer complications. |
| Type of condition and stage | Treatment usually works better for minimally aggressive conditions that are in their early stages. |
| Type of transplant used | The choice between autologous and allogeneic, can influence outcomes based on condition type. |
Nutrition and Immune Support After Transplant
Recovery does not end with the HSCT transplant itself. It requires more than just time—a comprehensive focus on rebuilding the immune system, maintaining proper nutrition, and regaining physical strength. Patients can more quickly and safely regain their quality of life with a customized recovery plan that includes physical rehabilitation, infection prevention, and nutritional support.
Frequently Asked Questions
1. How does hematopoietic stem cell transplantation work?
The HSCT procedure replaces damaged bone marrow with healthy hematopoietic stem cells. This helps the body produce normal blood and immune cells again.
2. What is HSCT treatment cost?
The hematopoietic stem cell transplantation cost depends on the country, the type of transplant, and the hospital stay length. Many patients explore HSCT cost options abroad, especially at HSCT Europe centers.
3. What steps are involved in the hematopoietic stem cell transplantation procedure?
The HSCT process includes evaluation, donor search, conditioning, transplant, and recovery. Each step is carefully planned by expert medical teams.
Contact us
Are you seeking guidance on advanced medical treatment options?
Simply complete the brief application form below, and one of our specialists will contact you to arrange a personalized, no-cost consultation.
Medical Advisor, Swiss Medica doctor
List of References
Khaddour K, Hana CK, Mewawalla P. Hematopoietic Stem Cell Transplantation. [Updated 2023 May 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536951/
Malgorzata Mikulska, Francesca Gualandi, Paola Anserini, Chapter 10 – Early and late complications of hematopoietic stem cell transplantation, Editor(s): Matilde Inglese, Giovanni L. Mancardi, Handbook of Clinical Neurology, 2024, https://doi.org/10.1016/B978-0-323-90242-7.00010-9.
Tan EY, Boelens JJ, Jones SA, Wynn RF. Hematopoietic Stem Cell Transplantation in Inborn Errors of Metabolism. Front Pediatr. 2019 Oct 25;7:433. doi: 10.3389/fped.2019.00433. PMID: 31709204; PMCID: PMC6824291.
Tan EY, Boelens JJ, Jones SA, Wynn RF. Hematopoietic Stem Cell Transplantation in Inborn Errors of Metabolism. Front Pediatr. 2019 Oct 25;7:433. doi: 10.3389/fped.2019.00433. PMID: 31709204; PMCID: PMC6824291.
Burns SO, Morris EC. How I use allogeneic HSCT for adults with inborn errors of immunity. Blood. 2021 Nov 4;138(18):1666-1676. doi: 10.1182/blood.2020008187. PMID: 34077952.
Morita-Fujita M, Arai Y, Yoshioka S, Ishikawa T, Kanda J, Kondo T, Akasaka T, Ueda Y, Imada K, Moriguchi T, Yago K, Kitano T, Yonezawa A, Nohgawa M, Takaori-Kondo A; Kyoto Stem Cell Transplantation Group (KSCTG). Indication and benefit of upfront hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma in the era of ALL-type induction therapies. Sci Rep. 2020 Dec 8;10(1):21418. doi: 10.1038/s41598-020-78334-x. PMID: 33293600; PMCID: PMC7722931.
Sailor, K.A., Agoranos, G., López-Manzaneda, S. et al. Hematopoietic stem cell transplantation chemotherapy causes microglia senescence and peripheral macrophage engraftment in the brain. Nat Med 28, 517–527 (2022). https://doi.org/10.1038/s41591-022-01691-9